At the 2023 Society for Immunotherapy of Cancer meeting, TILT Biotherapeutics revealed Phase I results for its solo TILT-123 treatment. The firm, a pioneer in cancer immunotherapies, uses this oncolytic virus to activate T-cells, targeting patients with progressive solid tumors.

On October 26th, 2023, KangaBio announced that the FDA has formally approved their clinical trial application for the independently developed KGX101, a fusion protein recombined with IL-12 Fc for intravenous injection. Clinical trials will be held simultaneously in Australia and the US.

Sensei Biotherapeutics, Inc. revealed initial results from its Phase 1/2 trial's sole therapy dose-increase part for SNS-101, a selectively active human antibody targeting the VISTA immune checkpoint.

REGENXBIO Inc. reveals positive additional results from ongoing Phase II ALTITUDE® study. The study pertains to ABBV-RGX-314, expected for treating diabetic retinopathy except center-involved diabetic macular edema, and is given through in-office suprachoroidal delivery.

Ankyra Therapeutics has published encouraging preclinical results for the combined use of ANK-101, a new anchored immune therapy, and cytotoxic chemotherapy in a head and neck cancer model.

Scholar Rock shares fresh results from its phase 1 DRAGON trial, indicating anti-tumor potential in patients with metastatic ccRCC who are resistant to Anti-PD-1. The data also backs the ongoing tolerability of SRK-181.

Cue Biopharma shares encouraging results from Phase 1 studies for CUE-101 for Head and Neck Cancer, and CUE-102 for Wilms' Tumor 1 related cases, at the SITC 2023 event.

At the 38th Society for Immunotherapy of Cancer Meeting, Adagene Inc. presented new data on its anti-CTLA-4 SAFEbody ADG126, revolutionizing new antibody-related therapies.

Kodiak Sciences recently revealed that its Phase III GLOW study of tarcocimab tedromer, a 5 mg ABC therapy for moderate to severe NPDR, met its primary one-year endpoint.

Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).

Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.